ESR1 and cancer: We analyzed potential effects of E2 on activation of HSF1 using a range of established breast cell lines, i.e., two non-tumorigenic (MCF10a and MCF12a) and four originated from cancer patients (MCF7, SKBR3, MDA-MB-468, BT-547) with a different ER status (Figure 1A).